 Proto-Oncogene Proteins B-raf
"Proto-Oncogene Proteins B-raf" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A raf kinase subclass found at high levels in neuronal tissue. The B-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2.
| Descriptor ID |
D048493
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.559.842.374 D12.644.360.400.842.374 D12.776.476.400.842.437 D12.776.624.664.700.204.200
|
| Concept/Terms |
Proto-Oncogene Proteins B-raf- Proto-Oncogene Proteins B-raf
- B-raf, Proto-Oncogene Proteins
- Proteins B-raf, Proto-Oncogene
- Proto Oncogene Proteins B raf
- Proto-Oncogene Protein B-raf
- B-raf, Proto-Oncogene Protein
- Protein B-raf, Proto-Oncogene
- Proto Oncogene Protein B raf
- B-raf Kinases
- B raf Kinases
- BRAF Kinases
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins B-raf".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins B-raf".
This graph shows the total number of publications written about "Proto-Oncogene Proteins B-raf" by people in this website by year, and whether "Proto-Oncogene Proteins B-raf" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 3 | 0 | 3 | | 2006 | 1 | 3 | 4 | | 2008 | 0 | 1 | 1 | | 2010 | 5 | 2 | 7 | | 2011 | 6 | 7 | 13 | | 2012 | 6 | 4 | 10 | | 2013 | 8 | 4 | 12 | | 2014 | 3 | 5 | 8 | | 2015 | 4 | 0 | 4 | | 2016 | 2 | 1 | 3 | | 2017 | 3 | 3 | 6 | | 2018 | 5 | 3 | 8 | | 2019 | 5 | 5 | 10 | | 2020 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins B-raf" by people in Profiles.
-
Huijberts SCFA, Boelens MC, Bernards R, Opdam FL. Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib. Br J Cancer. 2021 01; 124(1):176-182.
-
Shu S, Matsuzaki J, Want MY, Conway A, Benjamin-Davalos S, Allen CL, Koroleva M, Battaglia S, Odunsi A, Minderman H, Ernstoff MS. An Immunosuppressive Effect of Melanoma-derived Exosomes on NY-ESO-1 Antigen-specific Human CD8+ T Cells is Dependent on IL-10 and Independent of BRAFV600E Mutation in Melanoma Cell Lines. Immunol Invest. 2020 Oct; 49(7):744-757.
-
Mambetsariev I, Wang Y, Chen C, Nadaf S, Pharaon R, Fricke J, Amanam I, Amini A, Bild A, Chu P, Erhunmwunsee L, Kim J, Munu J, Pillai R, Raz D, Sampath S, Vora L, Qiu F, Smith L, Batra SK, Massarelli E, Koczywas M, Reckamp K, Salgia R. Precision medicine and actionable alterations in lung cancer: A single institution experience. PLoS One. 2020; 15(2):e0228188.
-
Poklepovic AS, Luke JJ. Considering adjuvant therapy for stage II melanoma. Cancer. 2020 03 15; 126(6):1166-1174.
-
Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, Geoerger B, Hingorani P, Dunkel IJ, Russo MW, Tseng L, Dasgupta K, Gasal E, Whitlock JA, Kieran MW. Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. Clin Cancer Res. 2019 12 15; 25(24):7303-7311.
-
Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53.
-
Cipriani NA. Prognostic Parameters in Differentiated Thyroid Carcinomas. Surg Pathol Clin. 2019 Dec; 12(4):883-900.
-
Kieran MW, Geoerger B, Dunkel IJ, Broniscer A, Hargrave D, Hingorani P, Aerts I, Bertozzi AI, Cohen KJ, Hummel TR, Shen V, Bouffet E, Pratilas CA, Pearson ADJ, Tseng L, Nebot N, Green S, Russo MW, Whitlock JA. A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors. Clin Cancer Res. 2019 12 15; 25(24):7294-7302.
-
Luke JJ. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. Oncologist. 2019 11; 24(11):e1197-e1211.
-
Tan C, Mueller JL, Noviski M, Huizar J, Lau D, Dubinin A, Molofsky A, Wilson PC, Zikherman J. Nur77 Links Chronic Antigen Stimulation to B Cell Tolerance by Restricting the Survival of Self-Reactive B Cells in the Periphery. J Immunol. 2019 05 15; 202(10):2907-2923.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|